1) The therapy has not been in clinical trial.
2) Natural killer (NK) cells Kill viral infected cells, and induce inflammatory responses, so if the therapy is shown to be effective, it will be used to treat early infection and not those whom already have ARDS. deciding who to give their NK cells is a question they have to find out as the therapy won’t be cheap and the majority of patients only have mild disease
for these reasons I wouldn’t be concern that this is a direct competitor of mesoblast
1) The therapy has not been in clinical trial. 2) Natural killer...
-
- There are more pages in this discussion • 16,878 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.060(4.12%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.39 | $1.930M | 1.377M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 44458 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 14820 | 13 |
View Market Depth
| Last trade - 11.40am 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |